A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.

ABSTRACT: To make an optimal treatment decision for early stage breast cancer, it is important to identify risk of recurrence. Here, we developed and validated a new prognostic model for predicting the risk of distant metastasis in patients with pN0-N1, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer treated with hormone therapy alone. RNA was extracted from formalin-fixed, paraffin-embedded tumor tissues and gene expression was measured by quantitative real-time reverse transcription-PCR. The relative expression of six novel prognostic genes was combined with two clinical variables (nodal status and tumor size) to calculate a risk score (BCT score). In the validation cohort treated with hormone therapy alone, the 10 year rate of distant metastasis in the high-risk group (26.3%) a

SUBMITTER: Gong G 

PROVIDER: S-EPMC5368569 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature